LifeMD (NASDAQ:LFMD) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of LifeMD (NASDAQ:LFMD) from a hold rating to a sell rating in a research note published on Saturday.

LFMD has been the subject of a number of other research reports. Loop Capital set a $10.00 price objective on shares of LifeMD in a research note on Thursday, March 12th. Weiss Ratings raised shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday. HC Wainwright boosted their price objective on shares of LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Mizuho raised shares of LifeMD from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Stock Up 6.5%

Shares of NASDAQ:LFMD opened at $4.78 on Friday. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The stock has a market cap of $231.16 million, a P/E ratio of 95.62 and a beta of 2.03. The business’s 50 day moving average is $3.87 and its 200 day moving average is $3.93.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The firm had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. On average, sell-side analysts anticipate that LifeMD will post 0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeMD

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD in the fourth quarter worth $36,000. Magnus Financial Group LLC purchased a new position in LifeMD in the fourth quarter worth $41,000. R Squared Ltd purchased a new position in LifeMD in the first quarter worth $41,000. Jain Global LLC purchased a new position in LifeMD in the fourth quarter worth $45,000. Finally, Quarry LP purchased a new position in LifeMD in the third quarter worth $52,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.